These findings emphasize the potential for SGIP1 and rs7549881 to serve as therapeutic targets, not only in Parkinsonism but also in addressing the broader gut-brain axis, which may influence both neurological and gastrointestinal health. This evidence concerns the gene SGIP1 and Parkinsonism.